Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR0B1 | P51843 | 1/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.51 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.51 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SLC2A9 | Q9NRM0 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31734123 | 0.92 | NR0B1 (0.78) | NR0B1ADORA3MEN1KMT2ANPC1 | |
| Cytochalasin D SCHEMBL25847004 | 0.89 | NR0B1 (1.00) | NR0B1ADORA3MEN1KMT2ANPC1 | |
| Cytochalasin D SCHEMBL33529 | 0.89 | NR0B1 (1.00) | NR0B1ADORA3MEN1KMT2ANPC1 | |
| Cytochalasin D SCHEMBL29375699 | 0.89 | NR0B1 (1.00) | NR0B1ADORA3MEN1KMT2ANPC1 | |
| Cytochalasin D SCHEMBL33528 | 0.89 | NR0B1 (1.00) | NR0B1ADORA3MEN1KMT2ANPC1 | |
| Cytochalasin D SCHEMBL12648577 | 0.89 | NR0B1 (1.00) | NR0B1ADORA3MEN1KMT2ANPC1 | |
| Cytochalasin D SCHEMBL31734099 | 0.89 | NR0B1 (1.00) | NR0B1ADORA3MEN1KMT2ANPC1 | |
| Cytochalasin D SCHEMBL16502284 | 0.89 | NR0B1 (1.00) | NR0B1ADORA3MEN1KMT2ANPC1 | |
| SCHEMBL33772 | 0.87 | ADORA3 (0.80) | NR0B1ADORA3MEN1KMT2ANPC1 | |
| SCHEMBL29745878 | 0.81 | NR0B1 (0.86) | NR0B1ADORA3MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062904-A1 | STENT COATING | ICON INTERVENTIONAL SYSTEMS, INC. | 2009-03-05 | — | — | US | claimed |
| US-20260070124-A1 | METHOD FOR FORMING A TUBE | MIRUS LLC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4404878-A1 | COATING FOR REFRACTORY METAL ALLOY | MiRus LLC (US) | 2024-07-31 | — | — | EP | disclosed |
| EP-1858440-B1 | IMPROVED METAL ALLOYS FOR MEDICAL DEVICE | MIRUS LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20240024542-A1 | METAL ALLOYS FOR METAL DEVICES | MIRUS LLC | 2024-01-25 | — | — | US | disclosed |
| US-20230390454-A1 | STENT DEVICE FOR SPINAL FUSION | MIRUS LLC | 2023-12-07 | — | — | US | disclosed |
| US-11779685-B2 | Metal alloys for medical devices | MIRUS LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11766506-B2 | Stent device for spinal fusion | MIRUS LLC (US) | 2023-09-26 | — | — | US | disclosed |
| EP-3316826-B1 | MOLYBDENUM ALLOYS FOR MEDICAL DEVICES | MIRUS LLC (US) | 2023-04-19 | — | — | EP | disclosed |
| WO-2023048840-A1 | COATING FOR REFRACTORY METAL ALLOY | MIRUS LLC (US) | 2023-03-30 | — | — | WO | disclosed |
| WO-1998043618-A2 | USE OF CYTOSKELETAL INHIBITORS FOR THE PREVENTION OF RESTENOSIS | NEORX CORPORATION (US) | 1998-10-08 | — | — | WO | disclosed |
| US-5811447-A | Therapeutic inhibitor of vascular smooth muscle cells | NEORX CORPORATION (US) | 1998-09-22 | — | — | US | disclosed |
| EP-0702557-A4 | THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS | NEORX CORP (US) | 1998-06-03 | — | — | EP | disclosed |
| US-5733925-A | ADMINISTERING TAXOL TREATING CARDIOVASCULAR DISORDER | NEORX CORPORATION (US) | 1998-03-31 | — | — | US | disclosed |
| EP-0809515-A1 | THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS | NEORX CORPORATION (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1996025176-A1 | THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS | NEORX CORPORATION (US) | 1996-08-22 | — | — | WO | disclosed |
| EP-0702557-A1 | THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS | NEORX CORPORATION (US) | 1996-03-27 | — | — | EP | disclosed |
| EP-0681475-A1 | THERAPEUTIC INHIBITORS OF VASCULAR SMOOTH MUSCLE CELLS | NEORX CORPORATION (US) | 1995-11-15 | — | — | EP | disclosed |
| WO-1994026291-A1 | THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS | NEORX CORPORATION (US) | 1994-11-24 | — | — | WO | disclosed |
| WO-1994016706-A1 | THERAPEUTIC INHIBITORS OF VASCULAR SMOOTH MUSCLE CELLS | NEORX CORPORATION (US) | 1994-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070124-A1 | METHOD FOR FORMING A TUBE | NIT2, NFE2L2, DUOX2 | NR0B1 2547/4885ADORA3 3123/4885MEN1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.